STOCK TITAN
  1. Home
  2. News
  3. CTIC

CTI BioPharma Corp - CTIC STOCK NEWS

Welcome to our dedicated news page for CTI BioPharma (Ticker: CTIC), a resource for investors and traders seeking the latest updates and insights on CTI BioPharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CTI BioPharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CTI BioPharma's position in the market.

News
Sobi completes acquisition of CTI BioPharma Corp.
Rhea-AI Summary
Swedish Orphan Biovitrum AB (Sobi) has completed the acquisition of CTI BioPharma Corp (CTI) for USD 1.7 billion. Sobi purchased all outstanding shares of CTI through a tender offer and subsequent merger. CTI will now become an indirect wholly owned subsidiary of Sobi and its common stock will no longer be traded on NASDAQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-100%
Tags
acquisition
-
News
Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.
Rhea-AI Summary
Swedish Orphan Biovitrum AB (Sobi) has completed its tender offer to purchase all outstanding shares of common stock of CTI BioPharma Corp. (CTI) at a price of USD 9.10 per share in cash. Approximately 83.8 percent of CTI's outstanding shares were tendered and not withdrawn. The acquisition is expected to be completed on June 26, 2023, through a merger without a vote or meeting of CTI's stockholders. CTI will become a wholly owned subsidiary of Sobi, and its common stock will cease to be traded on NASDAQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders
Rhea-AI Summary
CTI BioPharma cancels 2023 Annual Meeting of Stockholders due to ongoing tender offer by Swedish Orphan Biovitrum AB (publ) to acquire all outstanding common stock of CTI. Transaction expected to close by Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
News
Sobi to Acquire CTI BioPharma
Rhea-AI Summary
CTI BioPharma announced that it will be acquired by Swedish Orphan Biovitrum AB (Sobi) in a $1.7 billion all-cash transaction. The acquisition will diversify Sobi's portfolio and enhance its commercial footprint in the U.S. CTI will become a wholly owned subsidiary of Sobi, and both companies aim to develop innovative medicines for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
85.27%
Tags
acquisition
-
News
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
-
News
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
none
News
CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences earnings
-
News
CTI BioPharma Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
-
News
CTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.03%
Tags
conferences
News
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
none
Stock CTIC logo
CTI BioPharma Corp

Nasdaq:CTIC

CTIC Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CTIC Stock Data

1.20B
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Seattle

About CTIC

cti was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. we strive to do business better than other biopharmaceutical companies. better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. a willingness to push the limits to achieve challenging goals is the essential attribute that sets cti employees apart.